BridgeBio Pharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held on June 17, 2021. BridgeBio Pharma, Inc. (BBIO) is a Delaware corporation with its principal executive offices in Palo Alto, CA. The filing details the voting outcomes for four proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
At the Annual Meeting, 131,658,614 shares were present or represented by valid proxy out of 149,330,911 shares entitled to vote. The following proposals were approved:
- Proposal 1 (Election of Directors): Three Class II director nominees were elected to serve until the 2024 Annual Meeting.
- Eric Aguiar, M.D.: 112,441,149 votes for; 8,264,997 votes withheld.
- Ali Satvat: 109,399,398 votes for; 11,306,748 votes withheld.
- Jennifer E. Cook: 112,740,211 votes for; 7,965,935 votes withheld.
- Proposal 2 (Say-on-Pay): Stockholders approved the compensation of Named Executive Officers on a non-binding advisory basis.
- Votes For: 104,049,614
- Votes Against: 12,951,661
- Abstentions: 3,704,871
- Proposal 3 (Frequency of Say-on-Pay): Stockholders recommended an annual frequency for advisory votes on executive compensation.
- 1-Year Option: 115,723,204 votes (98.90% of votes cast).
- 2-Year Option: 801,492 votes.
- 3-Year Option: 480,332 votes.
- Proposal 4 (Auditor Ratification): Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 131,492,849
- Votes Against: 144,598
- Abstentions: 21,167
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the tabulation of votes.
Key Facts for Investor Verification
- Verify the total number of shares entitled to vote (149,330,911) against the company's latest 10-K or 10-Q to confirm share count accuracy.
- Confirm the tenure of the newly elected directors (Eric Aguiar, Ali Satvat, Jennifer E. Cook) through the 2024 Annual Meeting.
- Note the strong shareholder preference for annual executive compensation advisory votes (98.90% support).
- Review the proxy statement referenced in the filing for detailed biographies of the elected directors and specific executive compensation figures.